Oral sesame oil-based formulation facilitates the delivery of poorly water-soluble drug cannabidiol (CBD) to the lymphatic system and blood circulation. However, this natural oil-based formulation also leads to considerable variability in…

Oral cannabidiol (CBD) is approved by the Food and Drug Administration (FDA) to treat patients with Dravet and Lennox-Gastaut syndromes, and tuberous sclerosis complex. The therapeutic potential of oral CBD formulations is limited by…

Obtaining orodispersible tablets (ODT) containing substances from the 2nd Biopharmaceutical Class has raised concerns as the dissolution test is challenging. This study aimed to select suitable excipients for developing orodispersible…

Cannabidiol (CBD) is an alkaloid that can be found in the Cannabis species, currently used in United States of America under the name of Epidiolex®, which was approved by Food and Drug Administration (FDA) for seizures treatment. The…

Stability studies represent an essential component of pharmaceutical development, enabling critical evaluation of the therapeutic potential of an active pharmaceutical ingredient (API) or a final pharmaceutical product under the influence…

During the last decade, an innovative lab on a chip technology known as microfluidics became popular in the pharmaceutical field to produce nanomedicines in a scalable way. Nevertheless, the predominant barriers for new microfluidics users…

In this study, the general processability of cannabidiol (CBD) in colloidal lipid carriers was investigated. Due to its many pharmacological effects, the pharmaceutical use of this poorly water-soluble drug is currently under intensive…

Thursday, 4 March 2021 – 02:30 PM CET In this webinar, you can ask the experts from BENEO everything you always wanted to know about galenIQ™. Recent trends show that patients and consumers want to take their medicine and nutritional…